Hydrochloric Acid

Hydrochloric Acid

SCHEMBL1045367

Cl.c1ccc2c(c1)N(C1CCCCC1)CN2C1CCCCC1

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
OPRM1 known ✓ P35372 4/20 0.42
OPRK1 known ✓ P41145 4/20 0.42
OPRD1 known ✓ P41143 1/20 0.42
GAA known ✓ P10253 1/20 0.41
HSD11B1 known ✓ P28845 1/20 0.40
HTR2C known ✓ P28335 2/20 0.37
HTR2B known ✓ P41595 2/20 0.37
OGFRL1 Q5TC84 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SLC18A3 Q16572 1/20 0.40
POLB P06746 1/20 0.39
OPRL1 P41146 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28132082 1.00 OPRM1 (0.42) OPRM1OPRK1OPRD1OGFRL1MEN1
SCHEMBL1043568 0.98 OPRM1 (0.43) OPRM1OPRK1OPRD1OGFRL1MEN1
SCHEMBL4934890 0.72 HTR2C (0.58) OPRM1OPRK1OPRD1MEN1KMT2A
SCHEMBL30673810 0.71 OPRM1 (0.41) OPRM1OPRK1OPRD1OGFRL1MEN1
SCHEMBL27971621 0.71 SLC18A3 (0.41) OPRM1OPRK1OPRD1OGFRL1MEN1
SCHEMBL180964 0.71 BCHE (0.41) OPRM1OPRK1OPRD1OGFRL1MEN1
SCHEMBL30600476 0.71 BCHE (0.41) OPRM1OPRK1OPRD1OGFRL1MEN1
SCHEMBL21307175 0.71 HTR2C (0.60) OPRM1OPRK1OPRD1MEN1KMT2A
SCHEMBL21307179 0.71 HTR2C (0.60) OPRM1OPRK1OPRD1MEN1KMT2A
SCHEMBL29091543 0.71 GAA (0.58) OPRM1OPRK1OPRD1OGFRL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117069770-A Method for synthesizing N-heterocyclic carbene complex by utilizing hydrogen bond 石河子大学 2023-11-17 CN claimed
CN-117069770-A Method for synthesizing N-heterocyclic carbene complex by utilizing hydrogen bond 石河子大学 2023-11-17 CN disclosed
US-20190177265-A1 METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND DOW AGROSCIENCES LLC (US) 2019-06-13 US disclosed
US-20190077744-A1 METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND DOW AGROSCIENCES LLC 2019-03-14 US disclosed
EP-3429987-A1 METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND Dow Global Technologies LLC (US) 2019-01-23 EP disclosed
US-10125082-B2 Method for coupling a first compound to a second compound DOW GLOBAL TECHNOLOGIES LLC (US) 2018-11-13 US disclosed
US-20180237459-A1 METHOD FOR COUPLING AN AROMATIC OR VINYLIC COMPOUND TO A BORON-CONTAINING COMPOUND DOW GLOBAL TECHNOLOGIES LLC (US) 2018-08-23 US disclosed
US-20180237363-A1 METHOD FOR COUPLING AN AROMATIC COMPOUND TO AN ALKYNE DOW GLOBAL TECHNOLOGIES LLC (US) 2018-08-23 US disclosed
EP-3337808-A1 METHOD FOR COUPLING AN AROMATIC OR VINYLIC COMPOUND TO A BORON-CONTAINING COMPOUND Dow Global Technologies LLC (US) 2018-06-27 EP disclosed
EP-3337783-A1 METHOD FOR COUPLING AN AROMATIC COMPOUND TO AN ALKYNE Dow Global Technologies LLC (US) 2018-06-27 EP disclosed
WO-2016057770-A1 METHOD FOR COUPLING A FLUOROSULFONATE COMPOUND WITH AN AMINE COMPOUND DOW GLOBAL TECHNOLOGIES LLC (US) 2016-04-14 WO disclosed
WO-2016057771-A1 METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND DOW GLOBAL TECHNOLOGIES LLC (US) 2016-04-14 WO disclosed
US-20160000757-A1 METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2016-01-07 US disclosed
WO-2015148931-A1 METHOD FOR COUPLING A FIRST AROMATIC COMPOUND TO A SECOND AROMATIC COMPOUND DOW GLOBAL TECHNOLOGIES LLC (US) 2015-10-01 WO disclosed
US-9072729-B2 Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-07-07 US disclosed
EP-2803356-A1 Method for treating neurological disorders with imidazolium and imidazolinium compounds Agency for Science, Technology and Research (SG) 2014-11-19 EP disclosed
US-20110178040-A1 METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2011-07-21 US disclosed
US-20110028513-A1 METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2011-02-03 US disclosed
EP-2271338-A1 METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS Agency for Science, Technology And Research (SG) 2011-01-12 EP disclosed
WO-2009123569-A1 METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180237459-A1 METHOD FOR COUPLING AN AROMATIC OR VINYLIC COMPOUND TO A BORON-CONTAINING COMPOUND PAH, BCL6, BLVRB OPRM1 4276/4885OPRK1 3577/4885OPRD1 4051/4885
US-20110028513-A1 METHOD FOR TREATING NEUROLOGICAL DISORDERS WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS SMN1; SMN2, INA, NLN OPRM1 3394/4885OPRK1 2040/4885OPRD1 3439/4885
US-20110178040-A1 METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS MMP1, MYLK, MMP8 OPRM1 4432/4885OPRK1 4177/4885OPRD1 4782/4885
US-20190077744-A1 METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND CA6, CA2, NUDT21 OPRM1 4503/4885OPRK1 4573/4885OPRD1 4828/4885
US-20180237363-A1 METHOD FOR COUPLING AN AROMATIC COMPOUND TO AN ALKYNE ALK, TYR, AHR OPRM1 3400/4885OPRK1 2354/4885OPRD1 3419/4885
US-20190177265-A1 METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND PAICS, NUDT21, TIAL1 OPRM1 3583/4885OPRK1 3543/4885OPRD1 4616/4885
US-10125082-B2 Method for coupling a first compound to a second compound SQLE, FDPS, PAICS OPRM1 3612/4885OPRK1 3494/4885OPRD1 4482/4885
US-20160000757-A1 METHOD FOR TREATING FIBROSIS AND CANCER WITH IMIDAZOLIUM AND IMIDAZOLINIUM COMPOUNDS MMP1, MYLK, MMP8 OPRM1 4432/4885OPRK1 4177/4885OPRD1 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.